Recalls & Warnings September 26, 2012 Maker of Eye Health Supplements Warned for Drug Claims On September 18, 2012, the FDA issued a warning letter to EyeScience Labs, L.L.C
Our physicians evaluate your specific needs to determine if this multi-peptide approach is more appropriate than single-peptide therapy for your situation
Technical Specifications Flexible formats and strengths for your brand Our Glutathione Range A selection of formulations we produce - every product is fully private-label with your branding
The clinical implication: treating constipation with anti-nausea strategies (ginger, small meals, etc.) doesn't work because you're targeting the wrong organ
Patients interested in peptide treatments should only pursue them under the direct supervision of qualified medical experts
BPC-157 appears better suited for systemic and deep tissue applications, particularly gastrointestinal protection, musculoskeletal repair, and neuroprotection, where its multi-pathway mechanism of action addresses complex healing processes
